https://www.blueskyvaccines.com/ 2025-12-17T11:34+00:00 https://www.blueskyvaccines.com/imprint-en/ 2021-12-13T11:41+00:00 https://www.blueskyvaccines.com/privacy-en/ 2023-08-15T06:54+00:00 https://www.blueskyvaccines.com/blog-en/ 2021-12-13T11:34+00:00 https://www.blueskyvaccines.com/immunotherapy-clinical-trial/ 2023-08-09T12:00+00:00 https://www.blueskyvaccines.com/immunotherapy-cancer-equine-sarcoids/ 2023-08-09T10:35+00:00 https://www.blueskyvaccines.com/immunotherapy-hpv-16-phase-1-clinical-trial/ 2023-08-09T10:35+00:00 https://www.blueskyvaccines.com/no-access/ 2023-12-06T18:00+00:00 https://www.blueskyvaccines.com/oropharyngeal-cancer-treatment-phase-1-trial/ 2024-03-08T12:47+00:00 https://www.blueskyvaccines.com/landmark-in-hpv-treatment-excellent-safety-and-substantial-efficacy-of-viral-vector-delns-e6e7-in-phase-1-trial/ 2025-12-15T10:43+00:00 https://www.blueskyvaccines.com/bluesky-immunotherapies-reaches-milestone-with-delns-viral-vector-for-opscc-treatment/ 2025-02-28T23:55+00:00 https://www.blueskyvaccines.com/phase-1-trial-oropharyngeal-cancer-treatment/ 2024-03-07T18:04+00:00 https://www.blueskyvaccines.com/delns-technology-makes-tumours-vulnerable-to-the-immune-system/ 2023-08-09T11:08+00:00 https://www.blueskyvaccines.com/sarcoids-in-horses-next-milestone-in-cancer-therapy/ 2023-08-15T06:56+00:00 https://www.blueskyvaccines.com/patent-protection-for-innovative-technology-platform-en/ 2023-08-15T06:59+00:00